The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM IN BRIEF: Quindell And ValiRx Placings; Noricum Gold Positive Results

Fri, 15th Nov 2013 07:53

LONDON (Alliance News) - The following AIM-listed companies are making headlines on Alliance News Professional at the market open Friday:
----------
Quindell Portfolio Raises GBP200M Through Share Placing
----------
Bglobal Enters Agreement With Future Energy Solutions For Nutech Training
----------
Northbridge Industrial Services Acquires Assets of Oilfield Material Management For USD3M
----------
Armadale Capital To Buy Rest Of Netcom Global; Deal Gives It 80% Interest In Mpokoto Gold Project
----------
London Capital Finance Director Steps Down; Appoints Interim Finance Chief While It Looks For Successor
----------
Physiomics FY Turnover Up 77% To GBP240,000 Vs GBP135,306; Operating Loss Of GBP548,342 Vs GBP577,922; FY Net Loss Of GBP500,571 Vs GBP539,577; Signed A SEDA Structured Equity Deal, Won A Feasibility Grant
----------
Parkmead Group FY Pretax Loss GBP5.3M Vs GBP4.9M; Revenue Up 38% To GBP4.1 Million; FY Total Assets GBP53.4M Vs GBP22.9M; In Advanced Talks With Debt Lenders
----------
Noricum Gold: Results Continue To Reinforce High Grade Nature Of Rotguloden Project ; Visible Gold Intersected In Drill Hole C9; Drilling On-Going Underground; Looks Forward To Further Positives In Near Future
----------
GW Phamaceuticals Orphan Drug Designation Granted For Epidiolex In Dravet Syndrome By FDA
----------
Touchstone Gold Q3 Net Loss USD499,350 Vs USD2.3M; 9-Mo Net Loss USD16.9M Vs USD7.7M
----------
ValiRx To Raises GBP1M Through Share Placing
----------
Doriemus Reorganises Board, Don Strang New Chairman
----------
Frontier IP Makes New Spin-Out Company With Plymouth University; Receives 21% Stake In New Spin-Out Company PulsiV Solar
----------
Matchtech Chairman: Q1 Trading In Line With Board Expectations; Demand For Contract Recruitment Continues To Grow; Seeing First Signs Of Permanent Candidate Confidence Returning; Q1 Net Fee Income Of GBP11.1M, Up 13%; Looks Forward With Confidence To The Year Ahead
----------
Pantheon Resources FY Loss GBP700,095 Vs GBP703,602
----------
Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

Read more
14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

Read more
6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Raises GBP200,000 To Progress Product Development

Read more
16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

Read more
28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

Read more
28 Nov 2019 15:57

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

Read more
14 Oct 2019 13:44

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

Read more
26 Sep 2019 11:43

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

Read more
24 Sep 2019 12:40

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Read more
10 Sep 2019 13:45

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

Read more
1 Aug 2019 12:01

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

Read more
23 Jul 2019 16:25

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

Read more
26 Jun 2019 14:30

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

Read more
26 Jun 2019 10:53

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.